Oct 15
In this episode of the ACT Podcast, Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and TransCelerate program lead at Merck, discuss the findings from a recent TransCelerate and Tufts CSDD study revealing that nearly one-third of data collected in Phase III trials is non-essential.
Listen to the full podcast by Applied Clinical Trials here.
Related Blog Posts
Trendspotting: Embracing AI, DEI Changes, Restrategizing Research Sites
To kick off 2026, we spoke with industry experts and leaders in the Clinical Research News community about what they expect and look forward to in the new year. More than ever before, artificial intelligence took center stage. Read the full article featuring Allison Cuff Shimooka from Clinical Research News here.
Trendspotting: Artificial Intelligence, Impact of Global Policies, Data Harmonization
To kick off 2026, we spoke with industry experts and leaders in the Bio-IT World community about what they expect and look forward to in the new year. Read the full article featuring Allison Cuff Shimooka from Bio-It World here.
More 2026 Clinical Predictions
This is part 2 of my article about predictions for the clinical trials industry in 2026. From my reporting on AI growing pains, site-network shakeups, and the never-ending sponsor–site tension over feasibility and budgets, it’s clear the industry is carrying plenty of unresolved business into the new year. Read the full article featuring Rob DiCicco…